A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention

Status unconfirmed · Phase 2

Conditions studied: Glaucoma

In brief

A. To evaluate the ocular hypotensive efficacy of the rho-kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in open-angle glaucoma patients with uncontrolled IOP who are facing surgical intervention. Patients will be treated for 6 months in this initial trial. B. To evaluate the efficacy of AR-12286 in enabling treated patients to delay or avoid the necessity of surgical intervention.

Key facts

Study ID

NCT02174991

Run by

New York Glaucoma Research Institute

People needed

10

Starts

2014-06-01

Last updated by the study team

2015-04-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with open-angle glaucoma.
• IOP above the target range or visual field progression with use of maximum standard drug therapy.
• Have given written informed consent, prior to any investigational procedures.
• Ability to attend for the 6-month duration of treatment.

You may not qualify if…

• Angle-closure glaucoma
• Eyes having had previous incisional glaucoma surgery
• Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
• Ocular medication of any kind within 30 days of base-line visit, with the exception of ocular hypotensive medications and/or lubricating drops for dry eye (which may be used throughout the study).
• Any abnormality preventing reliable applanation tonometry of the treated eye.
• Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
• Participation in any investigational study within the past 30 days.
• Inability to perform reliable visual field testing.
• Unwilling to sign the consent form approved by the Institutional Review Board (IRB) of the New York Eye and Ear Infirmary.
• Self-reported poor compliance to treatment.
• Reluctance to return for scheduled follow-up visits.
• Patients not able to understand the nature of the study.

Where it is running

• Glaucoma Associates of New York — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.